Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.58 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | UMPS | P11172 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.52 |
| ▸ | KRAS | P01116 | 2/20 | 0.51 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14948862 | 1.00 | P2RX3 (0.61) | P2RX3P2RY2TGM2UMPSP2RY6 | |
| SCHEMBL29868101 | 0.99 | P2RX3 (0.60) | P2RX3P2RY2TGM2UMPSP2RY6 | |
| SCHEMBL15038134 | 0.91 | P2RY2 (0.53) | P2RX3P2RY2TGM2UMPSP2RY6 | |
| SCHEMBL16160997 | 0.90 | UMPS (0.51) | P2RX3P2RY2TGM2UMPSP2RY6 | |
| SCHEMBL5315097 | 0.85 | TGM2 (0.58) | P2RX3P2RY2TGM2P2RY6P2RY4 | |
| SCHEMBL5315091 | 0.85 | TGM2 (0.58) | P2RX3P2RY2TGM2P2RY6P2RY4 | |
| SCHEMBL17893049 | 0.85 | PNP (0.66) | P2RX3P2RY2TGM2P2RY6P2RY4 | |
| SCHEMBL14930893 | 0.84 | P2RX3 (0.44) | P2RX3P2RY2TGM2UMPSP2RY6 | |
| SCHEMBL154964 | 0.84 | POLB (0.55) | P2RX3P2RY2P2RY6P2RY4FUT5 | |
| SCHEMBL15794376 | 0.84 | TGM2 (0.59) | P2RX3P2RY2TGM2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240309447-A1 | METHODS AND KITS FOR PREPARING A SAMPLE COMPRISING ONE OR MORE RNA MOLECULES FOR SEQUENCING | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-09-19 | — | — | US | claimed |
| WO-2018119117-A1 | METHODS OF PRODUCING CYCLIC DINUCLEOTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-28 | — | — | WO | claimed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | claimed |
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2026-01-29 | — | — | US | disclosed |
| EP-4534700-A2 | REFERENCE LADDERS AND ADAPTORS | Garvan Institute of Medical Research (AU) | 2025-04-09 | — | — | EP | disclosed |
| EP-4527010-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | Centre National de la Recherche Scientifique (FR) | 2025-03-26 | — | — | EP | disclosed |
| US-20240309447-A1 | METHODS AND KITS FOR PREPARING A SAMPLE COMPRISING ONE OR MORE RNA MOLECULES FOR SEQUENCING | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-09-19 | — | — | US | disclosed |
| CN-117797164-A | Medicine for preventing and treating tumor and application thereof | 北京医院 | 2024-04-02 | — | — | CN | disclosed |
| US-11920174-B2 | RNA analysis by total hydrolysis and quantification of released nucleosides | CureVac SE (DE) | 2024-03-05 | — | — | US | disclosed |
| WO-2024036284-A1 | GENERATION AND SELECTION OF AFFINITY REAGENTS | NAUTILUS SUBSIDIARY, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230392187-A1 | REFERENCE LADDERS AND ADAPTORS | GARVAN INSTITUTE OF MEDICAL RESEARCH (AU) | 2023-12-07 | — | — | US | disclosed |
| WO-2023223068-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-11-23 | — | — | WO | disclosed |
| EP-4103749-A1 | REFERENCE LADDERS AND ADAPTORS | Garvan Institute of Medical Research (AU) | 2022-12-21 | — | — | EP | disclosed |
| US-20220351807-A1 | BIOCOMPATIBLE NUCLEIC ACIDS FOR DIGITAL DATA STORAGE | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4038616-A1 | BIOCOMPATIBLE NUCLEIC ACIDS FOR DIGITAL DATA STORAGE | Centre national de la recherche scientifique (FR) | 2022-08-10 | — | — | EP | disclosed |
| WO-2018119117-A1 | METHODS OF PRODUCING CYCLIC DINUCLEOTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-28 | — | — | WO | disclosed |
| US-20140170689-A1 | Modified Diguanylate Cyclase-Phosphodiesterase and Method for Enzymatic Production of Cyclic-diGMP | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-06-19 | — | — | US | disclosed |
| US-20050123937-A1 | Methods for the electrochemical detection of target compounds | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2005-06-09 | — | — | US | disclosed |
| WO-2004092708-A2 | METHODS FOR THE ELECTROCHEMICAL DETECTION OF TARGET COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028621-A1 | METHOD FOR ENCODING DIGITAL DATA ON NUCLEIC ACIDS USING BIOLOGICAL PROCESSES | NSUN2, RNMT, RNGTT | P2RX3 676/4885P2RY2 496/4885TGM2 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.